Moderna (NASDAQ:MRNA) experienced a significant rally on Friday, with shares climbing 12.6% on heavy trading volume following the company's Science Day announcements. The stock closed at $67.27, marking a 5.2% gain for the week and reversing earlier declines. The surge was driven by investor enthusiasm over Moderna's expansion into in vivo CAR-T therapy, a novel approach to treating autoimmune diseases.
Market Performance and Volume
The jump was accompanied by a notable increase in trading activity, with 14.46 million shares changing hands on Friday—more than double Thursday's volume of 6.80 million. Shares traded between $59.23 and $69.285, closing near the session high. Moderna's performance outpaced the broader healthcare sector, as the SPDR S&P Biotech ETF (XBI) rose 2.45%, the iShares Nasdaq Biotechnology ETF (IBB) added 1.99%, and the Vanguard Health Care ETF (VHT) gained 2.82%. In contrast, the S&P 500 dipped 0.05% and the Nasdaq fell 0.24%, weighed down by declines in chip stocks.
Analyst Price Targets and Valuation
Despite the rally, Moderna shares trade at a significant premium to the consensus analyst price target. According to MarketScreener, the mean target among 24 analysts is $44.25, with a consensus rating of "Hold." At Friday's close, the stock is approximately 52% above that average. However, Piper Sandler raised its price target to $77 from $69, maintaining an "Overweight" rating. The new target implies about 14.5% upside from current levels, up from just 2.6% under the previous target. The revision largely validates the bullish case following the Science Day updates.
Pipeline Developments and Science Day
The catalyst for the rally was Moderna's June 25 Science Day, where the company outlined its strategy to diversify beyond vaccines. CEO Stéphane Bancel emphasized the goal of becoming "a diversified, multi-modality biotechnology company," with new modalities such as in vivo CAR-T entering the clinic. The centerpiece of the update was mRNA-6007, an in vivo CAR-T asset targeting systemic lupus erythematosus and other B-cell autoimmune diseases. Chief Scientific Officer Lin Guey described it as the "sentinel programme designed to unlock a scalable in vivo CAR-T modality," noting its potential to "reset pathogenic B-cell immunity." The Horizon 3 programs may reach first-in-human trials by the end of 2027. The rally occurred despite the fact that mRNA-6007 remains preclinical and has not yet demonstrated human proof of concept.
Financial Position and Cash Burn
Moderna's financial health remains a point of focus. As of March 31, 2026, the company held $7.5 billion in cash, cash equivalents, and investments, down from $8.1 billion at the end of 2025. The company projects year-end 2026 cash and investments of $4.5 billion to $5.0 billion, with research and development costs expected to reach approximately $3.0 billion for the year. The ongoing cash burn underscores the need for successful pipeline advancement to justify the current valuation.
Near-Term Catalysts: Flu Vaccine
In the near term, Moderna's mRNA flu vaccine for adults 50 and older could provide support. On June 18, U.S. FDA advisers unanimously recommended approval, with a final FDA decision expected by August 5. However, Citi analyst Geoff Meacham noted that the vaccine, mFlusiva, is unlikely to generate meaningful revenue before the second half of 2027, as Moderna missed the 2026 U.S. contracting window. Jefferies' Andrew Tsai projects $750 million in combined U.S. sales of Moderna's flu shot and COVID-flu combo by 2030.
Trading Outlook
Looking ahead, the upcoming trading week will be shortened due to the Independence Day holiday. Nasdaq will be closed on Friday, July 3, 2026, with normal trading sessions Monday through Thursday. Investors will be watching for any further updates on pipeline progress and regulatory decisions.
